Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
BVI launches FINEVISION HP, a novel hydrophobic trifocal IOL based on the FINE optical technology platform, in Japan.
- FINEVISION HP is the first patented diffractive trifocal IOL and is one of the flagship products in BVI’s IOL portfolio; FINE Trifocal technology is utilized across the company’s entire range of presbyopia-correcting IOLs.
- The Japan launch follows two key FINEVISION HP 2023 milestones: One million FINEVISION IOL implants sold worldwide and the recent completion of the FINEVISION HP IDE clinical study patient enrollment in the US.
- BVI expects to introduce several IOL models over the next few years in Japan, demonstrating BVI’s commitment to ophthalmic surgeons and their patients in Japan.
WALTHAM, Mass., June 19th, 2023 (GLOBE NEWSWIRE) BVI, one of the fastest growing surgical ophthalmic businesses in the world, is thrilled to announce the official launch of FINEVISION HP in Japan. The FINEVISION HP hydrophobic and glistening free trifocal IOL represents a significant breakthrough in trifocal technology as the first trifocal platform to offer cataract patients high quality vision across all distances.
Given substantial excitement and interest in the product, BVI Japan has already received orders for FINEVISION HP and will host the official launch event at the upcoming Japanese Society of Cataract and Refractive Surgeons (JSCRS) annual meeting in Sapporo, Japan on June 22 through June 24. Dr. Kazunori Miyata (Miyata Eye Hospital), Dr. Hisaharu Suzuki (Zengyo Suzuki Eye Clinic), and Dr. Yousai Mori (Miyata Eye Hospital) will be presenting the results of the clinical trial conducted in Japan.
As part of BVI’s commitment to continuously improve product performance to meet patients’ and surgeons’ needs, the FINEVISION HP IOL is now in its third generation since the initial FINE optical technology platform was launched in 2010. BVI has developed this unique IOL with numerous novel designs, including proprietary, patented hydrophobic material, a one-of-a-kind double C loop haptic design, and patented CoPODize™ optical surface technologies which enables Convolution and Apodization across the entire optic zone. As the trifocal market leader in Europe, BVI has proven this technology with over 10 years of success and one million FINEVISION implants sold across the world.
Dr. Kazuo Ichikawa of Chukyo Eye Clinic, Nagoya said: “It is great to see a new option of Multifocal IOL lens for our patients in Japan. Not only was FINEVISION the original trifocal, but the new generation FINEVISION HP provides 20/20 vision from -3D to +.5D of defocus as well as controlling dysphotopsia.
Shervin Korangy, BVI President and CEO said: ‘‘I could not be more pleased with the feedback we are receiving from surgeons about their experience partnering with BVI. The FINEVISION launch in Japan continues to execute on our strategic vision of expanding into key markets globally. Our commitment to bring BVI’s world-class products to surgeons and patients across the world is unwavering and continues at an accelerated pace. I look forward to watching our team’s success with this and subsequent product launches in the Japanese market”.
About BVI
BVI® is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving the vision of patients. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors. Our trusted brands include Beaver® (Knives and Blades), Visitec® (Cannulas), Malosa® (Single-Use Instruments), Vitreq® (Vitreoretinal Surgical Products) and PhysIOL® (Premium IOLs).
For further enquiries or to speak to a BVI representative, please email Andrew Dawson, Head of BVI Corporate Communications: [email protected]
BVI Announces Complete Enrollment of FINEVISION® HP IDE Clinical Study
WALTHAM, MA – May 1, 2023 (GLOBE NEWSWIRE) — BVI, a diversified global ophthalmic device company, today announced it has completed enrollment of its U.S. Investigational Device Exemption (IDE) clinical study for its latest hydrophobic trifocal intraocular lens, FINEVISION® HP.
The milestone marks the final implantation of the 539th patient enrolled in the prospective, multicenter, randomized, masked, controlled IDE clinical study. Patients will now be followed to evaluate the safety and performance of the FINEVISION HP intraocular lens, with the results to form the basis for a regulatory submission to obtain marketing approval in the United States.
BVI has one of the most comprehensive ophthalmic surgery portfolios in the industry and is committed to expanding its availability globally.
“With the IDE clinical study completing both the enrollment and implantation phase in less than 12 months, we are pleased with our momentum and acknowledge the patients and clinical investigators for their commitment to the trial,” said Devang Shah, Ph.D., BVI Senior Vice President, Business Operations.
Shervin Korangy, BVI President and CEO, added, “Achieving this milestone represents an exciting and significant step towards bringing our IOL technology to US patients and surgeons. This trial is the first of a series of studies on innovative ophthalmic devices that BVI will be undertaking in the U.S. in the coming years.”
FINEVISION® HP is a hydrophobic trifocal IOL and the third generation in the FINEVISION® family, featuring BVI’s proprietary hydrophobic material and two novel patented CoPODize™ technologies enabling Convolution and Apodization concepts on the entire optic surface.
CAUTION FINEVISION® is CE Marked since 2010. FINEVISION® HP is an Investigational device in the United States. Limited by Federal Law to investigational use; Pending PMA, not available for sale within the United States.
About BVI
BVI® is a diversified global ophthalmic device company with a mission to deliver high quality solutions and innovation for advancing eye surgery and improving the vision of patients. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. BVI supports surgical teams in more than 90 countries worldwide, either directly or through its network of trusted distributors. BVI trusted brands include: Beaver® (Knives and Blades), Visitec® (Cannulas), Malosa® (Single-Use Instruments), Vitreq® (Vitreoretinal Surgical Products) and PhysIOL® (Premium IOLs).
Contacts
BVI
Andrew Dawson
Corporate Communications
Investors
Vivian Cervantes
Gilmartin Group
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
World Glaucoma Congress
28 June – 1 July, 2023
La Nuvola Roma Convention Center, Rome, Italy
Frankfurt Retina Meeting
15-16 April, 2023
Congress Centrum Mainz, Frankfurt
Cairo Retina Meeting
18-20 January, 2023
Discover BVI VR portfolio.
BVI Announces Certification for its Intraocular Lens Portfolio under the European Medical Device Regulation
WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) — BVI, a diversified global ophthalmic device company, today announced certification for its intraocular lens (IOL) portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medical Device Directive (MDD).
The MDR, representing the most significant change to European regulatory framework in decades, ensures a consistently high level of health and safety for medical devices. The new provisions focus on:
- Strict requirements with the intention to prove the safety of medical devices for both users and patients;
- Increased transparency of clinical evaluation, post market surveillance, and clinical investigation that needs to be up to date, clear, convincing, and publicly available;
- Greater emphasis on detailed requirements for technical documentation;
- Increased control and monitoring by national competent authorities and the EC;
- Reclassification of devices, wider scope of devices; and
- New Unique Device Identification system with enhanced traceability and post-market surveillance.
“Achieving and maintaining MDR certification is a major effort that requires a tremendous amount of investment, capabilities, and hard work,” said Shervin Korangy, BVI President and CEO. “This important milestone ensures continued supply of our innovative and clinically differentiated IOLS to our surgeons and patients worldwide.”
BVI Senior Vice President, Business Operations and Quality Assurance, Devang Shah, Ph.D. added, “We are proud to have obtained this certification, in partnership with our Notified Body BSI, which confirms BVI’s commitment to quality and compliance to the highest of regulatory standards. A recent MedTech report highlighted that Notified Bodies have yet to issue MDR certificates for more than 85% of the products certified under the prior directives² – so being at the forefront of this is a testament to our team’s expertise and dedication to our customers.”
About BVI
BVI® is a diversified global ophthalmic device company with a mission to deliver high quality solutions and innovation for advancing eye surgery and improving the vision of patients. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors. Our trusted brands include: Beaver® (Knives and Blades), Visitec® (Cannulas), Malosa® (Single-Use Instruments), Vitreq® (Vitreoretinal Surgical Products) and PhysIOL® (Premium IOLs).
![](https://www.bvimedical.co.uk/wp-content/uploads/2022/03/rome.jpg)
FLORetina
30 November - 4 December 2023
Rome Cavalieri Congress Center, Rome, Italy